title: Central neurocytoma: long-term outcomes of multimodal treatments and management strategies based on 30 years' experience in a single institute.
abstract: BACKGROUND
  A thorough investigation of the long-term outcomes of central neurocytoma (CN) after different treatments is required to establish optimal management strategies.
  
  
  OBJECTIVE
  We retrospectively reviewed the long-term clinical outcomes of patients with CN according to various treatments and suggest treatment strategies based on 30 years of experience in a single institution.
  
  
  METHODS
  Fifty-eight consecutive patients with CN were treated at our institution between 1982 and 2008. Patient demographics, overall survival, local control rates according to multimodal treatments, and functional outcomes were evaluated. The mean clinical and radiological follow-up periods were 119 months (range, 18-304 months) and 98 months (range, 13-245 months), respectively.
  
  
  RESULTS
  The initial treatment modality was classified into 4 subgroups: operation only (34 patients), operation followed by radiation therapy (7 patients) or radiosurgery (7 patients), and radiosurgery alone (10 patients). The actuarial overall survival was 91% at 5 years and 88% at 10 years. The actuarial overall survival and local tumor control rate did not differ significantly according to the various treatments and the initial extent of the surgical resection. However, functional outcomes, such as the postoperative seizure outcome at the last follow-up, differed according to the surgical approach.
  
  
  CONCLUSIONS
  The long-term clinical outcomes of CN after multimodal treatment seem to be excellent. Our study suggests that treatment strategies for CN should focus on the patient's quality of life, as well as on tumor control, because of the benign nature of CN.
authors.affiliation: Department of Neurosurgery, Seoul National University College of Medicine, Seoul, Korea. gknife@plaza.snu.ac.kr
authors.forename: Jin Wook
authors.initials: JW
authors.lastname: Kim
authors.forename: Dong Gyu
authors.initials: DG
authors.lastname: Kim
authors.forename: In Kyeong
authors.initials: IK
authors.lastname: Kim
authors.forename: Yong Hwy
authors.initials: YH
authors.lastname: Kim
authors.forename: Seung Hong
authors.initials: SH
authors.lastname: Choi
authors.forename: Jung Ho
authors.initials: JH
authors.lastname: Han
authors.forename: Chul-Kee
authors.initials: CK
authors.lastname: Park
authors.forename: Hyun-Tai
authors.initials: HT
authors.lastname: Chung
authors.forename: Sung-Hye
authors.initials: SH
authors.lastname: Park
authors.forename: Sun Ha
authors.initials: SH
authors.lastname: Paek
authors.forename: Hee-Won
authors.initials: HW
authors.lastname: Jung
mesh_terms: D000293:Adolescent; D000328:Adult; D001932:Brain Neoplasms / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D019090:Case Management; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D017567:Karnofsky Performance Status; D008297:Male; D008866:Microsurgery; D008875:Middle Aged; D018306:Neurocytoma / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D016634:Radiosurgery; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult